Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs) up to 21 days [clinicaltrials_resource:0d07388afe17458b89c9c7f25dbc29b6]
The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Tumor Necrosis Factor (TNF)-α Secretion by ex Vivo Lipopolysaccharide (LPS)-Stimulated Peripheral Blood Mononuclear Cells (PBMCs) up to 21 days [clinicaltrials_resource:0d07388afe17458b89c9c7f25dbc29b6]
The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response
Bio2RDF identifier
0d07388afe17458b89c9c7f25dbc29b6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0d07388afe17458b89c9c7f25dbc29b6
measure [clinicaltrials_vocabulary:measure]
Tumor Necrosis Factor (TNF)-α ...... lood Mononuclear Cells (PBMCs)
time frame [clinicaltrials_vocabulary:time-frame]
up to 21 days
description
The primary objective of the s ...... of the antimicrobial response
identifier
clinicaltrials_resource:0d07388afe17458b89c9c7f25dbc29b6
title
Tumor Necrosis Factor (TNF)-α ...... r Cells (PBMCs) up to 21 days
@en
type
label
Tumor Necrosis Factor (TNF)-α ...... 7388afe17458b89c9c7f25dbc29b6]
@en